|
SLC25A15 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.30479999991418E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
7.56399999968238E-07 |
| Normal-vs-Stage2 |
3.042200E-03 |
| Normal-vs-Stage3 |
2.49419999986955E-07 |
| Normal-vs-Stage4 |
9.27069998546415E-09 |
| Stage1-vs-Stage2 |
7.324100E-03 |
| Stage1-vs-Stage3 |
3.700600E-01 |
| Stage1-vs-Stage4 |
3.752700E-04 |
| Stage2-vs-Stage3 |
7.179200E-03 |
| Stage2-vs-Stage4 |
1.978650E-04 |
| Stage3-vs-Stage4 |
2.624000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.29959999989526E-07 |
| Normal-vs-AfricanAmerican |
1.495990E-02 |
| Normal-vs-Asian |
2.12590000048252E-08 |
| Caucasian-vs-AfricanAmerican |
5.012800E-01 |
| Caucasian-vs-Asian |
9.401400E-03 |
| AfricanAmerican-vs-Asian |
2.700400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.56749999985695E-07 |
| Normal-vs-Female |
1.42390000001935E-06 |
| Male-vs-Female |
2.711000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.06889999962334E-07 |
| Normal-vs-Age(41-60Yrs) |
1.22960000004113E-06 |
| Normal-vs-Age(61-80Yrs) |
8.07609999999848E-05 |
| Normal-vs-Age(81-100Yrs) |
2.362800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.394400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.216000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.699200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.942400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.740600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.950200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.13189999999086E-05 |
| Classical-VS-Follicular |
3.00139999998006E-06 |
| Classical-VS-Other |
1.637250E-01 |
| Classical-VS-Normal |
1.70600000015675E-07 |
| Tall-VS-Follicular |
2.01270000665943E-10 |
| Tall-VS-Other |
2.561000E-01 |
| Tall-VS-Normal |
2.71919997629766E-09 |
| Follicular-VS-Other |
1.03529999995189E-06 |
| Follicular-VS-Normal |
6.997700E-03 |
| Other-VS-Normal |
3.52060000041732E-08 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.86470000000028E-05 |
| Normal-vs-N1 |
9.0114999906632E-09 |
| N0-vs-N1 |
2.65190000003912E-06 |
|
|
